Article

Identification and characterization of a SARS-CoV-2 M <sup>pro</sup> G23 deletion ensitrelvir-resistant mutant

2025-10-07

Abstract excerpt

<h4>ABSTRACT</h4> Ensitrelvir is an antiviral drug that specifically targets the main protease (M pro ) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been approved for the treatment of coronavirus disease 2019 (COVID-19) due to the conservation of its target protein which is essential in the viral lifecycle. However, SARS-CoV-2 could introduce mutations in the viral proteins to confer resis...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e5fd4d54-5fef-5be0-a04b-39a2a02f9a2c
DOI: 10.1101/2025.09.30.679586

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification and characterization of a SARS-CoV-2 M <sup>pro</sup> G23 deletion ensitrelvir-resistant mutantDOI 10.1101/2025.09.30.679586Read

Identification and characterization of a SARS-CoV-2 Mpro G23 deletion ensitrelvir-resistant mutant.Semantic proximity Read

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read

A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.Semantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19Semantic proximity Read

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.Semantic proximity Read

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read